Title : Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.

Pub. Date : 2022 May 4

PMID : 35507130






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ex vivo treatment with the JAK1/2-inhibitor ruxolitinib reduced cytokine responsiveness and normalized STAT1 phosphorylation in DN STAT3 and STAT1 GOF patient" cells. ruxolitinib signal transducer and activator of transcription 3 Homo sapiens